Related Experiment Videos

Late closure of the ductus arteriosus using indomethacin in the preterm infant

M J Kresch1, F R Moya, R J Ascuitto

  • 1Department of Pediatrics Yale University School of Medicine, New Haven, CT 06510.

Clinical Pediatrics
|March 1, 1988
PubMed

Insights

Indomethacin may effectively close a patent ductus arteriosus (PDA) in preterm infants older than 20 days. Postconceptual age, not postnatal age, appears key for successful PDA treatment.

Area of Science:

  • Neonatal Medicine
  • Pediatric Cardiology
  • Pharmacology

Background:

  • Patent ductus arteriosus (PDA) is common in preterm infants.
  • Indomethacin is a standard treatment, but efficacy decreases after 14 days of postnatal age.
  • Hemodynamically significant PDAs pose risks like necrotizing enterocolitis and intraventricular hemorrhage.

Observation:

  • Two cases of preterm infants over 20 days old with hemodynamically significant PDAs successfully treated with indomethacin are presented.
  • These infants were under 34 weeks postconceptual age.
  • Response to indomethacin may correlate with postconceptual age rather than postnatal age.

Findings:

  • Intravenous indomethacin achieved closure of hemodynamically significant PDAs in preterm infants beyond the typical 14-day efficacy window.
  • Postconceptual age appears to be a more critical factor than postnatal age in determining indomethacin responsiveness for PDA closure.
  • Successful treatment in these cases suggests a potential role for indomethacin in select older preterm infants.

Implications:

  • Consideration of intravenous indomethacin therapy before surgical ligation for preterm infants under 34 weeks postconceptual age with hemodynamically significant PDAs.
  • This approach may reduce the need for surgical intervention and associated risks.
  • Further research is warranted to confirm the role of postconceptual age in guiding PDA treatment strategies.

Related Concept Videos